Hydrogen Peroxide 30 % Topical
Skin Squamous Cell Carcinoma
Explore 56 assets in Skin Squamous Cell Carcinoma →Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04929535CT.gov Hydrogen Peroxide Trial to Investigate the Efficacy of 30%H2O2 as a Topical Application Before Definitive Treatment | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Skin Squamous Cell Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Hydrogen Peroxide 30 % Topical (this asset) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | P2 | CCC · 53 |
| Prednisone | Dana-Farber Cancer Institute | P4 | BB |
| Sirolimus | Dana-Farber Cancer Institute | P4 | BB |
| Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer | Regeneron Pharmaceuticals | P3 | BB |
| Technetium-99 | Institut de Cancérologie de Lorraine | P3 | BB |
| Everolimus | Dana-Farber Cancer Institute | P4 | BB |
| Indocyanine Green | Institut de Cancérologie de Lorraine | P3 | BB |
| Cyclophosphamide | Merck Sharp & Dohme LLC | P2 | B |
| Nivolumab | Fred Hutchinson Cancer Center | P2 | B |
+42 more in the Skin Squamous Cell Carcinoma cohort
Other indications for Hydrogen Peroxide 30 % Topical
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Basal Cell Carcinoma | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- PrednisoneDana-Farber Cancer InstituteBB
- SirolimusDana-Farber Cancer InstituteBB
- Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, DimerRegeneron PharmaceuticalsBB
- Technetium-99Institut de Cancérologie de LorraineBB
- EverolimusDana-Farber Cancer InstituteBB
Citation
Floatz Terminal. Hydrogen Peroxide 30 % Topical in Skin Squamous Cell Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/hydrogen-peroxide-30-topical-skin-squamous-cell-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →